MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Proceeds from exercise ofstock options$31K Net cash provided byfinancing activities$13K Canceled cashflow$18K Net increase in cashand cash...-$15,759K Canceled cashflow$13K Stock-based compensation$2,085K Payroll-related accruals$841K Accounts payable$764K Other currentliabilities$733K Depreciation expense$342K Prepaid expenses andother current assets-$109K Non-cash lease expense$62K Interest receivable-$58K Other non-currentassets-$30K Lease liability$26K Redemptions of short-terminvestments$7,999K Payments for deferredinitial public offering...$18K Net cash used inoperating activities-$14,839K Net cash used ininvesting activities-$933K Canceled cashflow$5,050K Canceled cashflow$7,999K Net loss-$19,864K Purchases of short-terminvestments$7,000K Other receivables$25K Property and equipment$1,932K
Cash Flow

SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma, Inc. (SGP)

source: myfinsight.com